seekingalpha.com
/2 weeks ago
Latest updates for Rprx
Fresh curated links around RPRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
- Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside
- NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
seekingalpha.com
/1 month ago
Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside
seekingalpha.com
/1 week ago
NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
pharmexec.com
/1 month ago
<![CDATA[FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment ]]>
pharmexec.com
/1 month ago
<![CDATA[Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment]]>
finance.yahoo.com
/1 month ago
Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities
seekingalpha.com
/1 month ago
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
seekingalpha.com
/14 hours ago
Replimune got another attempt at lead drug after White House intervention: WSJ
seekingalpha.com
/4 weeks ago
Pacira BioSciences, Inc. 2026 Q1 - Results - Earnings Call Presentation
cantechletter.com
/3 weeks ago
Eupraxia wins new (US) $15.50 target at Leede Financial
Leede Financial analyst Douglas Loe raised his target on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials NASDAQ:EPRX) to US$15.50...
seekingalpha.com
/2 weeks ago
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program
cafepharma.com
/2 days ago
Blenrep
Blenrep Anonymous (not verified) Thu, 05/28/2026 - 11:40 field_thread_url https://cafepharma.com/boards/threads/blenrep.714532/ board na...
seekingalpha.com
/1 month ago
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
pharmexec.com
/2 weeks ago
<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>
seekingalpha.com
/1 month ago
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastati...
seekingalpha.com
/1 month ago
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare - Slideshow
finance.yahoo.com
/2 weeks ago
Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib
cafepharma.com
/3 weeks ago
Revolution Medicines
Revolution Medicines Anonymous (not verified) Tue, 05/05/2026 - 02:20 field_thread_url https://cafepharma.com/boards/threads/revolution-medicines.709803/...
seekingalpha.com
/4 weeks ago
Telix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX...
fool.com
/2 weeks ago
OptimizeRx (OPRX) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATETuesday, May 12, 2026, at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Stephen L. SilvestroChief Financial Officer — Edward StelmakhCh...
cafepharma.com
/1 month ago
FOR SALE
FOR SALE Anonymous (not verified) Wed, 04/22/2026 - 11:12 field_thread_url https://cafepharma.com/boards/threads/for-sale.708853/ board...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Rprx
seekingalpha.com
Recent coverage from public sources
Public source
cafepharma.com
Recent coverage from public sources
Public source
finance.yahoo.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
cantechletter.com
Recent coverage from public sources
Public source